BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 21851067)

  • 1. Development of novel efficient SIN vectors with improved safety features for Wiskott-Aldrich syndrome stem cell based gene therapy.
    Avedillo Díez I; Zychlinski D; Coci EG; Galla M; Modlich U; Dewey RA; Schwarzer A; Maetzig T; Mpofu N; Jaeckel E; Boztug K; Baum C; Klein C; Schambach A
    Mol Pharm; 2011 Oct; 8(5):1525-37. PubMed ID: 21851067
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improved lentiviral vectors for Wiskott-Aldrich syndrome gene therapy mimic endogenous expression profiles throughout haematopoiesis.
    Frecha C; Toscano MG; Costa C; Saez-Lara MJ; Cosset FL; Verhoeyen E; Martin F
    Gene Ther; 2008 Jun; 15(12):930-41. PubMed ID: 18323794
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A lentiviral vector encoding the human Wiskott-Aldrich syndrome protein corrects immune and cytoskeletal defects in WASP knockout mice.
    Charrier S; Stockholm D; Seye K; Opolon P; Taveau M; Gross DA; Bucher-Laurent S; Delenda C; Vainchenker W; Danos O; Galy A
    Gene Ther; 2005 Apr; 12(7):597-606. PubMed ID: 15616597
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of hematopoietic stem cell gene therapy for Wiskott-Aldrich syndrome.
    Boztug K; Dewey RA; Klein C
    Curr Opin Mol Ther; 2006 Oct; 8(5):390-5. PubMed ID: 17078381
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Retroviral WASP gene transfer into human hematopoietic stem cells reconstitutes the actin cytoskeleton in myeloid progeny cells differentiated in vitro.
    Dewey RA; Avedillo Díez I; Ballmaier M; Filipovich A; Greil J; Güngör T; Happel C; Maschan A; Noyan F; Pannicke U; Schwarz K; Snapper S; Welte K; Klein C
    Exp Hematol; 2006 Sep; 34(9):1161-9. PubMed ID: 16939809
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lentiviral haemopoietic stem/progenitor cell gene therapy for treatment of Wiskott-Aldrich syndrome: interim results of a non-randomised, open-label, phase 1/2 clinical study.
    Ferrua F; Cicalese MP; Galimberti S; Giannelli S; Dionisio F; Barzaghi F; Migliavacca M; Bernardo ME; Calbi V; Assanelli AA; Facchini M; Fossati C; Albertazzi E; Scaramuzza S; Brigida I; Scala S; Basso-Ricci L; Pajno R; Casiraghi M; Canarutto D; Salerio FA; Albert MH; Bartoli A; Wolf HM; Fiori R; Silvani P; Gattillo S; Villa A; Biasco L; Dott C; Culme-Seymour EJ; van Rossem K; Atkinson G; Valsecchi MG; Roncarolo MG; Ciceri F; Naldini L; Aiuti A
    Lancet Haematol; 2019 May; 6(5):e239-e253. PubMed ID: 30981783
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lentiviral vectors for enhanced gene expression in human hematopoietic cells.
    Ramezani A; Hawley TS; Hawley RG
    Mol Ther; 2000 Nov; 2(5):458-69. PubMed ID: 11082319
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hematopoietic-specific lentiviral vectors circumvent cellular toxicity due to ectopic expression of Wiskott-Aldrich syndrome protein.
    Toscano MG; Frecha C; Benabdellah K; Cobo M; Blundell M; Thrasher AJ; García-Olivares E; Molina IJ; Martin F
    Hum Gene Ther; 2008 Feb; 19(2):179-97. PubMed ID: 18240968
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of human Wiskott-Aldrich syndrome protein in patients' cells leads to partial correction of a phenotypic abnormality of cell surface glycoproteins.
    Huang MM; Tsuboi S; Wong A; Yu XJ; Oh-Eda M; Derry JM; Francke U; Fukuda M; Weinberg KI; Kohn DB
    Gene Ther; 2000 Feb; 7(4):314-20. PubMed ID: 10694812
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimization of adenovirus serotype 35 vectors for efficient transduction in human hematopoietic progenitors: comparison of promoter activities.
    Sakurai F; Kawabata K; Yamaguchi T; Hayakawa T; Mizuguchi H
    Gene Ther; 2005 Oct; 12(19):1424-33. PubMed ID: 15944730
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Validation of a mutated PRE sequence allowing high and sustained transgene expression while abrogating WHV-X protein synthesis: application to the gene therapy of WAS.
    Zanta-Boussif MA; Charrier S; Brice-Ouzet A; Martin S; Opolon P; Thrasher AJ; Hope TJ; Galy A
    Gene Ther; 2009 May; 16(5):605-19. PubMed ID: 19262615
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gene therapy for Wiskott-Aldrich syndrome--long-term efficacy and genotoxicity.
    Braun CJ; Boztug K; Paruzynski A; Witzel M; Schwarzer A; Rothe M; Modlich U; Beier R; Göhring G; Steinemann D; Fronza R; Ball CR; Haemmerle R; Naundorf S; Kühlcke K; Rose M; Fraser C; Mathias L; Ferrari R; Abboud MR; Al-Herz W; Kondratenko I; Maródi L; Glimm H; Schlegelberger B; Schambach A; Albert MH; Schmidt M; von Kalle C; Klein C
    Sci Transl Med; 2014 Mar; 6(227):227ra33. PubMed ID: 24622513
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lentiviral vectors transcriptionally targeted to hematopoietic cells by WASP gene proximal promoter sequences.
    Martín F; Toscano MG; Blundell M; Frecha C; Srivastava GK; Santamaría M; Thrasher AJ; Molina IJ
    Gene Ther; 2005 Apr; 12(8):715-23. PubMed ID: 15750617
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhanced transgene expression in cord blood CD34(+)-derived hematopoietic cells, including developing T cells and NOD/SCID mouse repopulating cells, following transduction with modified trip lentiviral vectors.
    Sirven A; Ravet E; Charneau P; Zennou V; Coulombel L; Guétard D; Pflumio F; Dubart-Kupperschmitt A
    Mol Ther; 2001 Apr; 3(4):438-48. PubMed ID: 11319904
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lentiviral vectors targeting WASp expression to hematopoietic cells, efficiently transduce and correct cells from WAS patients.
    Charrier S; Dupré L; Scaramuzza S; Jeanson-Leh L; Blundell MP; Danos O; Cattaneo F; Aiuti A; Eckenberg R; Thrasher AJ; Roncarolo MG; Galy A
    Gene Ther; 2007 Mar; 14(5):415-28. PubMed ID: 17051251
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gene therapy of primary T cell immunodeficiencies.
    Fischer A; Hacein-Bey-Abina S; Cavazzana-Calvo M
    Gene; 2013 Aug; 525(2):170-3. PubMed ID: 23583799
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Self-inactivating retroviral vectors with improved RNA processing.
    Kraunus J; Schaumann DH; Meyer J; Modlich U; Fehse B; Brandenburg G; von Laer D; Klump H; Schambach A; Bohne J; Baum C
    Gene Ther; 2004 Nov; 11(21):1568-78. PubMed ID: 15372067
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The combined use of viral transcriptional and post-transcriptional regulatory elements to improve baculovirus-mediated transient gene expression in human embryonic stem cells.
    Du J; Zeng J; Zhao Y; Boulaire J; Wang S
    J Biosci Bioeng; 2010 Jan; 109(1):1-8. PubMed ID: 20129073
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High levels of transgene expression following transduction of long-term NOD/SCID-repopulating human cells with a modified lentiviral vector.
    Gao Z; Golob J; Tanavde VM; Civin CI; Hawley RG; Cheng L
    Stem Cells; 2001; 19(3):247-59. PubMed ID: 11359950
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficient transcriptional targeting of human hematopoietic stem cells and blood cell lineages by lentiviral vectors containing the regulatory element of the Wiskott-Aldrich syndrome gene.
    Leuci V; Gammaitoni L; Capellero S; Sangiolo D; Mesuraca M; Bond HM; Migliardi G; Cammarata C; Aglietta M; Morrone G; Piacibello W
    Stem Cells; 2009 Nov; 27(11):2815-23. PubMed ID: 19785032
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.